

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number

30435.53USD1

Application Number

09/567.20

Applicant

Filing Date

May 8, 2000

Group Art Unit

1632

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT JH

Liu, A. Y., et al., "Prostatic Cell Lineage Markers: Emergence of BCL2⁺ Cells of Human Prostate Cancer Xenograft LuCaP 23 Following Castration," *Int. J. Cancer*, 65:85-89 (1996).Lubiaroff, D. M., et al., "Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2-Activated Lymphocytes in SCID Mice," *The Prostate*, 27:32-41 (1995).Wainstein, M. A., et al., "CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma," *Cancer Research*, 54:6049-6052 (1994).Pretlow, T. G., et al., "Xenografts of Primary Human Prostatic Carcinoma," *Journal of the National Cancer Institute*, 85(5):394-398 (1993).Pretlow, T. G., et al., "Transplantation of Human Prostatic Carcinoma into Nude Mice in Matrigel," *Cancer Research*, 51:3814-3817 (1991).Perez-Stable et al., *Cancer Research*, Vol. 57, Pages 900-906. (March 1, 1997).Sato et al., *Journal of Urology*, Vol. 155: 5, Page 338A. (May 4, 1996).van Weerden et al., *American Journal of Pathology*, Vol. 149: 3, Pages 1055-1062. (September 1996).COPY OF PAPERS
ORIGINALLY FILEDRECEIVED
MAY 22 2002
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE